Similar articles for PMID: 26943573

Year	Number of Results
2001	1
2002	1
2003	5
2004	8
2005	7
2006	13
2007	1
2008	4
2009	6
2010	8
2011	4
2012	2
2013	5
2014	9
2015	9
2016	11
2017	4
2018	7
2019	9
2020	5
2021	4
2024	0

1

Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.

Huang YH, Peng W, Furuuchi N, DuHadaway JB, Jimbo M, Pirritano A, Dunton CJ, Daum GS, Leiby BE, Brody JR, Sawicki JA. Huang YH, et al. Oncotarget. 2016 Apr 19;7(16):21812-24. doi: 10.18632/oncotarget.7840. Oncotarget. 2016. PMID: 26943573 Free PMC article.

2

dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.

McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR. McAllister F, et al. Cancer Biol Ther. 2014 Jun 1;15(6):688-98. doi: 10.4161/cbt.28413. Epub 2014 Mar 11. Cancer Biol Ther. 2014. PMID: 24618665 Free PMC article.

3

Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy.

Toyota K, Murakami Y, Kondo N, Uemura K, Nakagawa N, Takahashi S, Sueda T. Toyota K, et al. Ann Surg Oncol. 2018 May;25(5):1202-1210. doi: 10.1245/s10434-018-6392-y. Epub 2018 Feb 28. Ann Surg Oncol. 2018. PMID: 29492748

4

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.

Elebro J, Ben Dror L, Heby M, Nodin B, Jirström K, Eberhard J. Elebro J, et al. Acta Oncol. 2016;55(3):286-96. doi: 10.3109/0284186X.2015.1075663. Epub 2015 Sep 11. Acta Oncol. 2016. PMID: 26362587 Free PMC article.

5

HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.

Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, Sawicki JA, Winter JM, Rigoutsos I, Yen TJ, Brody JR. Lal S, et al. Cancer Res. 2014 Feb 15;74(4):1128-40. doi: 10.1158/0008-5472.CAN-13-1915. Cancer Res. 2014. PMID: 24536047 Free PMC article.

6

Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.

Sufliarsky J, Chovanec J, Svetlovska D, Minarik T, Packan T, Kroslakova D, Lalabova R, Helpianska L, Horvathova D, Sevcik L, Spacek J, Laluha A, Tkacova V, Malec V, Rakicka G, Magdin D, Jancokova I, Dorr A, Stresko M, Habetinek V, Koza I. Sufliarsky J, et al. Neoplasma. 2009;56(4):291-7. doi: 10.4149/neo_2009_04_291. Neoplasma. 2009. PMID: 19473054

7

pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.

Williams TK, Costantino CL, Bildzukewicz NA, Richards NG, Rittenhouse DW, Einstein L, Cozzitorto JA, Keen JC, Dasgupta A, Gorospe M, Gonye GE, Yeo CJ, Witkiewicz AK, Brody JR. Williams TK, et al. PLoS One. 2010 Nov 29;5(11):e15455. doi: 10.1371/journal.pone.0015455. PLoS One. 2010. PMID: 21152064 Free PMC article.

8

The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.

Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR. Costantino CL, et al. Cancer Res. 2009 Jun 1;69(11):4567-72. doi: 10.1158/0008-5472.CAN-09-0371. Cancer Res. 2009. PMID: 19487279 Free PMC article.

9

Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.

Pfisterer J, Vergote I, Du Bois A, Eisenhauer E; AGO-OVAR,; NCIC CTG; EORTC GCG. Pfisterer J, et al. Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:36-41. doi: 10.1111/j.1525-1438.2005.15355.x. Int J Gynecol Cancer. 2005. PMID: 15839957 Free article. Clinical Trial.

10

A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.

Eisenhauer EL, Zanagnolo V, Cohn DE, Salani R, O'Malley DM, Sutton G, Callahan MJ, Cobb B, Fowler JM, Copeland LJ. Eisenhauer EL, et al. Gynecol Oncol. 2014 Aug;134(2):262-6. doi: 10.1016/j.ygyno.2014.05.030. Epub 2014 Jun 5. Gynecol Oncol. 2014. PMID: 24910452 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

109 results

Results by year